Clinical Gastroenterology and Hepatology
Volume 3, Issue 4 , Pages 358-369, April 2005

An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial

  • Douglas L. Seidner

      Affiliations

    • Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationAddress requests for reprints to: Douglas L. Seidner, MD, Department of Gastroenterology\A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195fax: (216) 444-6305.
  • ,
  • Bret A. Lashner

      Affiliations

    • Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  • ,
  • Aaron Brzezinski

      Affiliations

    • Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  • ,
  • Phillip L.C. Banks

      Affiliations

    • STATPROBE, Dublin, Ohio, USA
  • ,
  • John Goldblum

      Affiliations

    • Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  • ,
  • Claudio Fiocchi

      Affiliations

    • Department of Gastroenterology, Case Western Reserve University, Cleveland, Ohio, USA
  • ,
  • Jeffry Katz

      Affiliations

    • Department of Gastroenterology, Case Western Reserve University, Cleveland, Ohio, USA
  • ,
  • Gary R. Lichtenstein

      Affiliations

    • Department of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania
  • ,
  • Peter A. Anton

      Affiliations

    • Department of Gastroenterology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California
  • ,
  • Lori Y. Kam

      Affiliations

    • Department of Gastroenterology, University of Southern California Medical Center, Los Angeles, California
  • ,
  • Keith A. Garleb

      Affiliations

    • Strategic Discovery R&D, Ross Products Division, Abbott Laboratories, Columbus, Ohio, USA
    • Drs Garleb and Demichele are employees of Ross Products Division, Abbott Laboratories.
  • ,
  • Stephen J. Demichele

      Affiliations

    • Strategic Discovery R&D, Ross Products Division, Abbott Laboratories, Columbus, Ohio, USA
    • Drs Garleb and Demichele are employees of Ross Products Division, Abbott Laboratories.
  • ,
  • The Enteral Nutrition in Ulcerative Colitis Study Group

published online 03 February 2005.

Background & Aims: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC. Methods: A total of 121 patients with UC and a disease activity index (DAI) from 3–9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model. Results: Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 ± 1.3; n = 36) compared with the placebo group (6.2 ± 2.0; n = 50) (P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (−2.5 for oral supplement and −2.8 for placebo) and histologic index (−1.9 for oral supplement vs. −2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group (P < .001). Conclusions: The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC.

Abbreviations used in this paper:  AA, arachidonic acid , DAI, disease activity index , DHA, docosahexaenoic acid , EPA, eicosapentaenoic acid , IBD, inflammatory bowel disease , SCFA, short-chain fatty acid , UC, ulcerative colitis , UCNS, ulcerative colitis nutritional supplement

 

 Supported in part by a grant from Ross Products Division, Abbott Laboratories.

PII: S1542-3565(04)00672-X

Clinical Gastroenterology and Hepatology
Volume 3, Issue 4 , Pages 358-369, April 2005